Oligonucleotide & ASO CDMOs — Ranked by Signal Score · 2026
Oligonucleotide / ASO manufacturers on CDMO Signal: 36 listed, 20 with a Signal Score. Together they have 36 FDA inspections on file (including 10 NAI, 26 VAI and 0 OAI) and 82 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure solid-phase synthesis scale, backbone chemistry, or conjugation. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-31. Methodology.
Oligo/ASO CDMOs with the most regulatory evidence on file
Shortlist oligonucleotide CDMOs with Signal
CDMO Signal is an independent sourcing platform ASO, siRNA, and aptamer sponsors use to compare and shortlist oligonucleotide CDMOs before an RFI. This page is the entry point — the ranked table below is derived from FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals. Use it to narrow the field, then verify chemistry, conjugation, scale, and analytical requirements directly with the shortlisted suppliers.
- Compare oligonucleotide CDMOs side-by-side on FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals — every number traceable to primary sources.
- Filter by regulatory jurisdiction, clean-inspection posture, and clinical-program breadth to your ASO, siRNA, or aptamer program's shortlisting criteria.
- Shortlist Use the ranked results to build your shortlist, then open each profile to review the underlying evidence before contacting suppliers. Follow up with the shortlisted CDMOs to verify chemistry, conjugation, scale, and analytical requirements directly.
Oligonucleotide CDMOs make antisense oligonucleotides (ASOs), siRNAs, and related nucleic-acid drugs by solid-phase synthesis, with downstream purification and conjugation (e.g. GalNAc). The segment has grown sharply alongside approved ASO and siRNA therapeutics.
Choosing an oligonucleotide CDMO turns on synthesis scale, chemistry breadth (phosphorothioate backbones, 2'-modifications, conjugation), purity, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 10 NAI (no action), 26 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: France (37), Italy (16), United States (16), Germany (12), Spain (10).
Last updated 2026-10-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
AJ
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 2 |
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
|
83.1 | 99.3 | 5 insp · 17 GMP | 2025-11-14 · NAI | — | — |
| 3 |
KE
Seraing, BE
|
81.6 | 99.9 | 1 insp · 4 GMP | 2024-02-26 · VAI | — | — |
| 4 |
ND
Milford, MA
|
80.3 | 100.0 | 4 insp · 0 GMP | 2026-08-12 · NAI | — | — |
| 5 |
BA
|
79.5 | 94.3 | 5 insp · 0 GMP | 2026-05-20 · VAI | — | — |
| 6 |
CRA
|
79.5 | 100.0 | 2 insp · 18 GMP | 2025-12-02 · NAI | — | — |
| 7 |
PP
|
77.4 | 98.4 | 3 insp · 0 GMP | 2025-05-15 · VAI | — | — |
| 8 |
AL
|
74.2 | 100.0 | 2 insp · 0 GMP | 2026-05-06 · NAI | — | 1 program |
| 9 |
AX
|
71.8 | 96.8 | 4 insp · 0 GMP | 2025-01-16 · VAI | — | 3 programs |
| 10 |
TL
|
63.0 | — | — | None on file | — | — |
| 11 |
LG
Petaluma, CA · Middleton, WI
|
63.0 | — | — | None on file | — | — |
| 12 |
SM
|
63.0 | — | — | None on file | — | — |
| 13 |
AU
Hyderabad, India
|
63.0 | — | — | None on file | — | — |
| 14 |
RR
Guangzhou, China
|
59.0 | — | — | None on file | — | — |
| 15 |
SP
Seoul, South Korea
|
59.0 | — | — | None on file | — | — |
| 16 |
HB
Singapore (primary operations: Union City, CA / Shanghai, China)
|
56.5 | — | — | None on file | — | — |
| 17 |
BS
|
56.5 | — | — | None on file | — | — |
| 18 |
CG2
|
56.5 | — | — | None on file | — | — |
| 19 |
MM
|
56.5 | — | — | None on file | — | — |
| 20 |
GR
|
56.5 | — | — | None on file | — | — |
| — |
|
Profiled | — | 4 insp · 39 GMP | 2024-03-08 · NAI | — | — |
| — |
Frankfurt am Main, Germany
|
Profiled | — | 1 insp · 0 GMP | 2022-11-15 · VAI | — | — |
| — |
|
Profiled | — | 2 insp · 3 GMP | 2024-10-18 · VAI | — | — |
| — |
Lianyungang, Jiangsu, China
|
Profiled | — | — | None on file | — | — |
| — |
|
Profiled | — | 1 insp · 0 GMP | 2026-08-21 · NAI | — | — |
| — |
|
Profiled | — | 1 insp · 0 GMP | 2023-05-12 · VAI | — | — |
| — |
|
Profiled | — | — | None on file | — | — |
| — |
|
Profiled | — | 1 insp · 0 GMP | 2025-10-24 · VAI | — | — |
| — |
Hyderabad, Telangana, India
|
Profiled | — | — | None on file | — | — |
| — |
Huizhou, Guangdong, China
|
Profiled | — | — | None on file | — | — |
| — |
Toyama, Japan
|
Profiled | — | — | None on file | — | — |
| — |
Rudong, Nantong, Jiangsu, China
|
Profiled | — | — | None on file | — | — |
| — |
|
Profiled | — | — | None on file | — | — |
| — |
|
Profiled | — | — | None on file | — | — |
| — |
|
Profiled | — | — | None on file | — | — |
| — |
Knoxville, Tennessee, USA
|
Profiled | — | — | None on file | — | — |